Neuropace Shares Are Trading Lower. The Company Reported Q2 Financial Results. Wells Fargo Lowered Its Price Target on the Stock From $20 to $15.
Neuropace Shares Are Trading Lower. The Company Reported Q2 Financial Results. Wells Fargo Lowered Its Price Target on the Stock From $20 to $15.
Neuropace股價下跌。該公司公佈了Q2業績。威爾斯·富高將該股票的目標價格從20美元下調至15美元。
Neuropace Shares Are Trading Lower. The Company Reported Q2 Financial Results. Wells Fargo Lowered Its Price Target on the Stock From $20 to $15.
Neuropace股價下跌。該公司公佈了Q2業績。威爾斯·富高將該股票的目標價格從20美元下調至15美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。